Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/715446/000149315221014032/form10-q.htm
SEC Filings
ANIX Annual Reports
ANIX Quarterly Reports
ANIX Corporate News
Event for Officers April 2022
Financial Exhibit
Regulated Disclosure
Vote of Security Holders March 2022
Shareholder Nomination December 2021
Regulated Disclosure October 2021
Other Events October 2021
Ending Agreement June 2021
Financial Exhibit
Regulated Disclosure
Vote of Security Holders May 2021
Bylaw Change
Event for Officers
Financial Exhibit April 2021
Financial Exhibit
New Agreement March 2021
New Agreement January 2021
Event for Officers
April 2022
Financial Exhibit
Regulated Disclosure
Vote of Security Holders
Regulated Disclosure
Vote of Security Holders
March 2022
Shareholder Nomination
December 2021
Regulated Disclosure
October 2021
Other Events
October 2021
Ending Agreement
June 2021
Financial Exhibit
Regulated Disclosure
Vote of Security Holders
Regulated Disclosure
Vote of Security Holders
May 2021
Bylaw Change
Event for Officers
Financial Exhibit
Event for Officers
Financial Exhibit
April 2021
Financial Exhibit
New Agreement
New Agreement
March 2021
New Agreement
January 2021
Last10K.com | 10-Q Quarterly Report Thu Jun 10 2021
Document and Entity Information - shares | 6 Months Ended | |
|---|---|---|
Apr. 30, 2021 | Jun. 10, 2021 | |
| Cover [Abstract] | ||
| Entity Registrant Name | Anixa Biosciences Inc | |
| Entity Central Index Key | 0000715446 | |
| Document Type | 10-Q | |
| Document Period End Date | Apr. 30, 2021 | |
| Amendment Flag | false | |
| Current Fiscal Year End Date | --10-31 | |
| Entity Current Reporting Status | Yes | |
| Entity Interactive Data Current | Yes | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Small Business Flag | true | |
| Entity Emerging Growth Company | false | |
| Entity Shell Company | false | |
| Entity Common Stock, Shares Outstanding | 29,949,905 | |
| Document Fiscal Period Focus | Q2 | |
| Document Fiscal Year Focus | 2021 |
View differences made from one quarter to another to evaluate Anixa Biosciences Inc's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Anixa Biosciences Inc.
Assess how Anixa Biosciences Inc's management team is paid from their Annual Proxy
Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
Tools
Rating
Learn More
Filter by Sentiment:
Filter by Category:
Filter by Subcategory:
-
Financial - Expense Highlight
The decrease in research and development expenses was primarily due to a decrease in outside research and development expense related to our cancer diagnostics program of approximately $305,000 and decreases in employee compensation and related costs, other than stock option compensation expense, of approximately $124,000 and employee stock option compensation expense of approximately $89,000, all due to the suspension of development of our cancer diagnostics program.
-
Financial - Expense Highlight
The decrease in research and development expenses was primarily due to a decrease in outside research and development expense related to our cancer diagnostics program of approximately $816,000 and decreases in employee compensation and related costs, other than stock option compensation expense, of approximately $394,000 and employee stock option compensation expense of approximately $194,000, all due to the suspension of development of our cancer diagnostics program.
-
Financial - Expense Highlight
21 Research and development expenses are related to the development of our cancer therapeutics, vaccine and diagnostics programs and our anti-viral drug program, and decreased by approximately $207,000 to approximately $1,022,000 in the three months ended April 30, 2021, from approximately $1,229,000 in the three months ended April 30, 2020.
-
Financial - Expense Highlight
Research and development expenses are related to the development of our cancer therapeutics, vaccine and diagnostics programs and our anti-viral drug program, and decreased by approximately $869,000 to approximately $1,850,000 in the six months ended April 30, 2021, from approximately $2,719,000 in the six months ended April 30, 2020.
-
Revenue - Product Highlight
Accordingly, the performance obligations from this license agreement were satisfied and 100% of the revenue was recognized upon execution of the license agreement.
-
Revenue - Product
Accordingly, the performance obligations from...Read more
-
Financial - Shares
Cash provided by financing activities...Read more
-
Other - Other
The net loss attributable to...Read more
-
Other - Other
23 The net loss attributable...Read more
-
Legal - Other
Inventor royalties, contingent legal fees,...Read more
-
Financial - Cash Flow
We can give no assurance...Read more
-
Revenue - Product
The increase was primarily due...Read more
-
Other - Other
As a result, our cash,...Read more
-
Revenue - Product
Cash used in investing activities...Read more
-
Financial - Expense
General and Administrative Expenses General...Read more
-
Financial - Expense
General and Administrative Expenses General...Read more
-
Financial - Income
Interest income decreased by approximately...Read more
-
Financial - Income
Interest income decreased by approximately...Read more
-
Financial - Expense
The increase in general and...Read more
-
Other - Other
We do not believe that...Read more
-
Revenue - Product
We believe that, of the...Read more
-
Revenue - Product
Our revenue arrangements provide for...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited) (Parenthetical)
Condensed Consolidated Statements Of Shareholders' Equity (Unaudited)
Condensed Consolidated Statements Of Shareholders' Equity (Unaudited) (Parenthetical)
Accrued Expenses
Accrued Expenses (Tables)
Accrued Expenses - Schedule Of Accrued Expenses (Details)
Business And Funding
Business And Funding (Details Narrative)
Business And Funding (Tables)
Business And Funding - Schedule Of Changes In Noncontrolling Interest (Details)
Commitments And Contingencies
Effect Of Recently Adopted And Issued Pronouncements
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Schedule Of Fair Value Measurements (Details)
Income Taxes
Income Taxes (Details Narrative)
Leases
Leases (Details Narrative)
Leases (Tables)
Leases - Schedule Of Minimum Lease Payments (Details)
Leases - Schedule Of Operating Lease (Details)
Net Loss Per Share Of Common Stock
Net Loss Per Share Of Common Stock (Details Narrative)
Public Offering
Public Offering (Details Narrative)
Segment Information
Segment Information (Details Narrative)
Segment Information (Tables)
Segment Information - Schedule Of Segment Information (Details)
Stock Based Compensation
Stock Based Compensation (Details Narrative)
Stock Based Compensation (Tables)
Stock Based Compensation - Schedule Of Option Activity (Details)
Stock Based Compensation - Schedule Of Outstanding And Exercisable (Details)
Material Contracts, Statements, Certifications & more
Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits
Ticker: ANIX
CIK: 715446
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-21-014032
Submitted to the SEC: Thu Jun 10 2021 4:30:49 PM EST
Accepted by the SEC: Thu Jun 10 2021
Period: Friday, April 30, 2021
Industry: Medical Laboratories
External Resources:
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/anix/0001493152-21-014032.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...